Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Blood blood.2024025945.

https://doi.org/10.1182/blood.2024025945

Published: 2024

Includes: Supplemental data

Journal Articles

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3499.

https://doi.org/10.1182/blood-2023-187565

Published: 2023

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Blood (2023) 142 (Supplement 1): 2011.

https://doi.org/10.1182/blood-2023-180013

Published: 2023

Journal Articles

The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma

Cesar Rodriguez, Aurore Perrot, Paul G. Richardson, Thierry Facon, Ivan Spicka, Albert Oriol, Kenshi Suzuki, Edvan Crusoe, Ajai Chari, Nicole Armstrong, Christina Tekle, Marie-Laure Risse, Thomas Martin, Philippe Moreau

Blood (2023) 142 (Supplement 1): 1980.

https://doi.org/10.1182/blood-2023-179925

Published: 2023

Journal Articles

Ablation of Cullin-5 in Primary Human T Cells Improves Tumor Killing and Persistence in BCMA-Targeting CAR-T Cells in a Multiple Myeloma Model

Stefanie Bachl, Alexis Talbot, Carter Ching, Nupura Kale, Zhongmei Li, Morgan Diolaiti, Amy Peixin Chen, Joseph Muldoon, Chang Liu, Thomas Martin, Justin Eyquem, Julia Carnevale

Blood (2023) 142 (Supplement 1): 99.

https://doi.org/10.1182/blood-2023-182565

Published: 2023

Journal Articles

Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Sireesha Asoori, Rakesh Popat, Joaquín Martínez-Lopez, Efstathios Kastritis, Larissa Brunaldi, Radhika Bansal, Andre De Menezes Silva Corraes, Kwee Yong, Catriona Mactier, Magdalena Corona, Adolfo Jesús Sáez Marín, Despina Fotiou, Meletios Athanasios Dimopoulos, Saurabh Chhabra, Sikander Ailawadhi, Ricardo Parrondo, Thomas Martin, Brian GM Durie, Yi Lin

Blood (2023) 142 (Supplement 1): 3347.

https://doi.org/10.1182/blood-2023-190793

Published: 2023

Journal Articles

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Blood (2023) 141 (3): 219–230.

https://doi.org/10.1182/blood.2022015526

Published: 2023

Includes: Supplemental data

Journal Articles

Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation

Kelsey H. Natsuhara, Chiung-Yu Huang, Jennifer Knoche, Shagun Arora, Alfred Chung, Thomas Martin, Jeffrey L. Wolf, Sandy W. Wong, Nina Shah, Rahul Banerjee

Blood (2022) 140 (Supplement 1): 7910–7912.

https://doi.org/10.1182/blood-2022-155906

Published: 2022

Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment

Marcelo Capra, Thomas Martin, Philippe Moreau, Gracia Martinez, Albert Oriol, Youngil Koh, Hang Quach, Kwee Yong, Andreea Rawlings, Christina Tekle, Sandrine Macé, Marie-Laure Risse, Ivan Spicka

Blood (2022) 140 (Supplement 1): 7138–7140.

https://doi.org/10.1182/blood-2022-162731

Published: 2022

Journal Articles

Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy

Kevin R Reyes, Yen-Chun Liu, Chiung-Yu Huang, Rahul Banerjee, Thomas Martin, Nina Shah, Sandy W. Wong, Jeffrey L. Wolf, Shagun Arora, Alfred Chung

Blood (2022) 140 (Supplement 1): 617–619.

https://doi.org/10.1182/blood-2022-160401

Published: 2022

Journal Articles

Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma

Kevin R. Reyes, Chiung-Yu Huang, Mimi Lo, Shagun Arora, Alfred Chung, Sandy W. Wong, Jeffrey L. Wolf, Thomas Martin, Nina Shah, Rahul Banerjee

Blood (2022) 140 (Supplement 1): 5105–5107.

https://doi.org/10.1182/blood-2022-160362

Published: 2022

Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis

Thierry Facon, Philippe Moreau, Ross Baker, Ludek Pour, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Lionel Karlin, Andreea Rawlings, Christina Tekle, Sandrine Schwab, Marie-Laure Risse, Thomas Martin

Blood (2022) 140 (Supplement 1): 1820–1822.

https://doi.org/10.1182/blood-2022-159105

Published: 2022

Journal Articles

Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing after or Refractory to Anti-BCMA CAR-T Therapies

Alfred Chung, Chiung-Yu Huang, Thomas Martin, Jeffrey L. Wolf, Sandy W. Wong, Nina Shah

Blood (2022) 140 (Supplement 1): 12651–12652.

https://doi.org/10.1182/blood-2022-170744

Published: 2022

Journal Articles

Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy

Aneeqa A Zafar, Chiung-Yu Huang, Mimi Lo, Jen Knoche, Shagun Arora, Alfred Chung, Sandy W. Wong, Jeffrey L. Wolf, Thomas Martin, Nina Shah, Rahul Banerjee

Blood (2022) 140 (Supplement 1): 5218–5220.

https://doi.org/10.1182/blood-2022-162122

Published: 2022

Journal Articles

Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy

Blood (2022) 140 (Supplement 1): 4646–4648.

https://doi.org/10.1182/blood-2022-158563

Published: 2022

Journal Articles

Outcomes in Patients with Renal Monoclonal Immunoglobulin Deposition Disease

Natasha S Bahri, Alfred Chung, Chiung-Yu Huang, Shagun Arora, Jeffrey L. Wolf, Thomas Martin, Nina Shah, Moming Li, Sandy W. Wong

Blood (2022) 140 (Supplement 1): 4285–4286.

https://doi.org/10.1182/blood-2022-167281

Published: 2022

Journal Articles

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

Nikhil C. Munshi, Bruno Paiva, Thomas Martin, Saad Usmani, Yi Lin, Jordan M. Schecter, Carolyn C. Jackson, Deepu Madduri, Enrique Zudaire, Tzu-min Yeh, J. Blake Bartlett, Lida Pacaud, Muhammad Akram, Dong Geng, Sundar Jagannath, Adam D. Cohen, Jesús San-Miguel

Blood (2022) 140 (Supplement 1): 4652–4654.

https://doi.org/10.1182/blood-2022-159141

Published: 2022

Journal Articles

A Real-World Study on the Feasibility of Minimal Residual Disease Testing By Next-Generation Sequencing in Systemic Light-Chain Amyloidosis

Sireesha Asoori, Alfred Chung, Nina Shah, Shagun Arora, Jeffrey L. Wolf, Thomas Martin, Sandy W. Wong

Blood (2022) 140 (Supplement 1): 7233–7234.

https://doi.org/10.1182/blood-2022-168451

Published: 2022

Journal Articles

Anakinra Targeting Cytokine Release Syndrome Associated with Chimeric Antigen Receptor T-Cell Therapies

Sandy W. Wong, Shambavi Richard, Yi Lin, Deepu Madduri, Carolyn C. Jackson, Enrique Zudaire, Vadim Romanov, Michael Trigg, Martin Vogel, Ashraf Garrett, Lisa Hullinger, Tonia Nesheiwat, Thomas Martin, Sundar Jagannath

Blood (2021) 138 (Supplement 1): 2812.

https://doi.org/10.1182/blood-2021-150592

Published: 2021

Journal Articles

Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 896.

https://doi.org/10.1182/blood-2021-147915

Published: 2021

NARROW

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma

Ablation of Cullin-5 in Primary Human T Cells Improves Tumor Killing and Persistence in BCMA-Targeting CAR-T Cells in a Multiple Myeloma Model

Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment

Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy

Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma

Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis

Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing after or Refractory to Anti-BCMA CAR-T Therapies

Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy

Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy

Outcomes in Patients with Renal Monoclonal Immunoglobulin Deposition Disease

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

A Real-World Study on the Feasibility of Minimal Residual Disease Testing By Next-Generation Sequencing in Systemic Light-Chain Amyloidosis

Anakinra Targeting Cytokine Release Syndrome Associated with Chimeric Antigen Receptor T-Cell Therapies

Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only